Cara Therapeutics | CARA - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Alterity Therapeutics Limited AUD 37.98M 15.78M 2025-12
Cara Therapeutics USD 25.82M 6.26M 2026-03
Cassava Sciences USD 108.37M 9.99M 2026-03
Chugai Pharma JPY 2.45T 184.81B 2026-06
Cipla INR 424.96B 23.32B 2026-03
Clal Biotechnology ILS 158.39M 24.3M 2023-12
Compugen USD 145.86M 10.71M 2026-03
CSL USD 37.9B 1.5B 2025-12
Grifols EUR 23.15B 142.7M 2025-12
Halozyme Therapeutics USD 2.58B 95.31M 2026-06
J&J USD 201.06B 167M 2026-06
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Pacira USD 1.24B 35.44M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
RedHill Biopharma USD 25.34M 6.97M 2025-12
Supernus Pharmaceuticals USD 1.43B 72.62M 2026-06
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12